Phillip B. Maples

Selective replication and oncolysis in p53 mutant tumors with ONYX-015, an E1B-55kD gene-deleted adenovirus, in patients with advanced head and neck cancer: a phase II trial.

John Nemunaitis, Ian Ganly, Fadlo R. Khuri et al. · PubMed · 2000 · 407 citations

Medicine, Cancer Biology, Oncology +16

Phase II Study of Belagenpumatucel-L, a Transforming Growth Factor Beta-2 Antisense Gene-Modified Allogeneic Tumor Cell Vaccine in Non–Small-Cell Lung Cancer

John Nemunaitis, Robert O. Dillman, Paul Schwarzenberger et al. · Journal of Clinical Oncology · 2006 · 359 citations · Full text

Medicine, Immunology, Oncology +17

Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease

Harry L. Malech, Phillip B. Maples, Narda Whiting‐Theobald et al. · Proceedings of the National Academy of Sciences · 1997 · 344 citations

Medicine, Hematology, Immunology +16

Intravenous infusion of a replication-selective adenovirus (ONYX-015) in cancer patients: safety, feasibility and biological activity

John Nemunaitis, Casey Cunningham, A Buchanan et al. · Gene Therapy · 2001 · 282 citations

Medicine, Clinical Pharmacokinetics, Oncology +14

A Phase I Study of Telomerase-specific Replication Competent Oncolytic Adenovirus (Telomelysin) for Various Solid Tumors

John Nemunaitis, Alex W. Tong, Michael Nemunaitis et al. · Molecular Therapy · 2009 · 267 citations · Full text

Medicine, Molecular Medicine, Oncology +13